Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer

M. A. Cobleigh*, K. Dowlatshahi, T. A. Deutsch, R. G. Mehta, R. C. Moon, F. Minn, A. B. Benson, A. W. Rademaker, J. B. Ashenhurst, J. L. Wade, J. Wolter

*Corresponding author for this work

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Purpose: Considerable attention has been focused on the chemopreventive properties of fenretinide against carcinogen-induced rodent mammary cancer. Less is known about its direct antitumor effects. The combination of tamoxifen and fenretinide is more effective than tamoxifen or fenretinide alone in prevention of rat mammary cancer. However, the combined toxicity of tamoxifen plus fenretinide in humans is unknown. Therefore, we performed a phase I/II trial in women with estrogen receptor (ER)-positive or progesterone receptor (PR)-positive, previously untreated metastatic breast cancer. Patients and Methods: Groups of three patients received tamoxifen 20 mg/d, or tamoxifen plus fenretinide 100, 200, 300, or 400 mg/d. Patients who received fenretinide enjoyed a 3-day 'drug holiday' every 4 weeks. Serum levels of fenretinide and its major metabolites were monitored. Patients were monitored for known toxicities of tamoxifen and vitamin A analogs, as well as for response. Results: There were no significant adverse effects on renal, hepatic, hematologic, or lipid values. Nyctalopia, photophobia, cheilitis, and pruritus were not observed. Improvement or stabilization of disease occurred in 12 of 15 patients. Conclusion: We conclude that tamoxifen administered with fenretinide is nontoxic. Phase III trials of tamoxifen versus tamoxifen plus fenretinide are warranted.

Original languageEnglish (US)
Pages (from-to)474-477
Number of pages4
JournalJournal of Clinical Oncology
Volume11
Issue number3
DOIs
StatePublished - Jan 1 1993

Fingerprint

Fenretinide
Tamoxifen
Vitamin A
Breast Neoplasms
Cheilitis
Night Blindness
Photophobia
Holidays
Progesterone Receptors
Pruritus
Estrogen Receptors
Carcinogens
Rodentia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cobleigh, M. A., Dowlatshahi, K., Deutsch, T. A., Mehta, R. G., Moon, R. C., Minn, F., ... Wolter, J. (1993). Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. Journal of Clinical Oncology, 11(3), 474-477. https://doi.org/10.1200/JCO.1993.11.3.474
Cobleigh, M. A. ; Dowlatshahi, K. ; Deutsch, T. A. ; Mehta, R. G. ; Moon, R. C. ; Minn, F. ; Benson, A. B. ; Rademaker, A. W. ; Ashenhurst, J. B. ; Wade, J. L. ; Wolter, J. / Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 3. pp. 474-477.
@article{e8d36bf3cafd4956bef5f8c3e308d120,
title = "Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer",
abstract = "Purpose: Considerable attention has been focused on the chemopreventive properties of fenretinide against carcinogen-induced rodent mammary cancer. Less is known about its direct antitumor effects. The combination of tamoxifen and fenretinide is more effective than tamoxifen or fenretinide alone in prevention of rat mammary cancer. However, the combined toxicity of tamoxifen plus fenretinide in humans is unknown. Therefore, we performed a phase I/II trial in women with estrogen receptor (ER)-positive or progesterone receptor (PR)-positive, previously untreated metastatic breast cancer. Patients and Methods: Groups of three patients received tamoxifen 20 mg/d, or tamoxifen plus fenretinide 100, 200, 300, or 400 mg/d. Patients who received fenretinide enjoyed a 3-day 'drug holiday' every 4 weeks. Serum levels of fenretinide and its major metabolites were monitored. Patients were monitored for known toxicities of tamoxifen and vitamin A analogs, as well as for response. Results: There were no significant adverse effects on renal, hepatic, hematologic, or lipid values. Nyctalopia, photophobia, cheilitis, and pruritus were not observed. Improvement or stabilization of disease occurred in 12 of 15 patients. Conclusion: We conclude that tamoxifen administered with fenretinide is nontoxic. Phase III trials of tamoxifen versus tamoxifen plus fenretinide are warranted.",
author = "Cobleigh, {M. A.} and K. Dowlatshahi and Deutsch, {T. A.} and Mehta, {R. G.} and Moon, {R. C.} and F. Minn and Benson, {A. B.} and Rademaker, {A. W.} and Ashenhurst, {J. B.} and Wade, {J. L.} and J. Wolter",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.3.474",
language = "English (US)",
volume = "11",
pages = "474--477",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. / Cobleigh, M. A.; Dowlatshahi, K.; Deutsch, T. A.; Mehta, R. G.; Moon, R. C.; Minn, F.; Benson, A. B.; Rademaker, A. W.; Ashenhurst, J. B.; Wade, J. L.; Wolter, J.

In: Journal of Clinical Oncology, Vol. 11, No. 3, 01.01.1993, p. 474-477.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer

AU - Cobleigh, M. A.

AU - Dowlatshahi, K.

AU - Deutsch, T. A.

AU - Mehta, R. G.

AU - Moon, R. C.

AU - Minn, F.

AU - Benson, A. B.

AU - Rademaker, A. W.

AU - Ashenhurst, J. B.

AU - Wade, J. L.

AU - Wolter, J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: Considerable attention has been focused on the chemopreventive properties of fenretinide against carcinogen-induced rodent mammary cancer. Less is known about its direct antitumor effects. The combination of tamoxifen and fenretinide is more effective than tamoxifen or fenretinide alone in prevention of rat mammary cancer. However, the combined toxicity of tamoxifen plus fenretinide in humans is unknown. Therefore, we performed a phase I/II trial in women with estrogen receptor (ER)-positive or progesterone receptor (PR)-positive, previously untreated metastatic breast cancer. Patients and Methods: Groups of three patients received tamoxifen 20 mg/d, or tamoxifen plus fenretinide 100, 200, 300, or 400 mg/d. Patients who received fenretinide enjoyed a 3-day 'drug holiday' every 4 weeks. Serum levels of fenretinide and its major metabolites were monitored. Patients were monitored for known toxicities of tamoxifen and vitamin A analogs, as well as for response. Results: There were no significant adverse effects on renal, hepatic, hematologic, or lipid values. Nyctalopia, photophobia, cheilitis, and pruritus were not observed. Improvement or stabilization of disease occurred in 12 of 15 patients. Conclusion: We conclude that tamoxifen administered with fenretinide is nontoxic. Phase III trials of tamoxifen versus tamoxifen plus fenretinide are warranted.

AB - Purpose: Considerable attention has been focused on the chemopreventive properties of fenretinide against carcinogen-induced rodent mammary cancer. Less is known about its direct antitumor effects. The combination of tamoxifen and fenretinide is more effective than tamoxifen or fenretinide alone in prevention of rat mammary cancer. However, the combined toxicity of tamoxifen plus fenretinide in humans is unknown. Therefore, we performed a phase I/II trial in women with estrogen receptor (ER)-positive or progesterone receptor (PR)-positive, previously untreated metastatic breast cancer. Patients and Methods: Groups of three patients received tamoxifen 20 mg/d, or tamoxifen plus fenretinide 100, 200, 300, or 400 mg/d. Patients who received fenretinide enjoyed a 3-day 'drug holiday' every 4 weeks. Serum levels of fenretinide and its major metabolites were monitored. Patients were monitored for known toxicities of tamoxifen and vitamin A analogs, as well as for response. Results: There were no significant adverse effects on renal, hepatic, hematologic, or lipid values. Nyctalopia, photophobia, cheilitis, and pruritus were not observed. Improvement or stabilization of disease occurred in 12 of 15 patients. Conclusion: We conclude that tamoxifen administered with fenretinide is nontoxic. Phase III trials of tamoxifen versus tamoxifen plus fenretinide are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0027512787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027512787&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.3.474

DO - 10.1200/JCO.1993.11.3.474

M3 - Article

VL - 11

SP - 474

EP - 477

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -